Mutation of human μ opioid receptor extracellular 'disulfide cysteine' residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane

Molecular Brain Research

Volumn 72, Issue 2, 1999, Pages 195-204

  Zhang, Peisu ^a   Johnson, Peter S ^a   Zöllner, Christian ^b   Wang, Wenfei ^b   Wang, Zaijie ^a   Montes, Anita E ^a   Seidleck, Brian K ^a   Blaschak, Carrie J ^a   Surratt, Christopher K ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Agonist; G protein; Morphine; Substance abuse

Indexed keywords

DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANINE NUCLEOTIDE BINDING PROTEIN; MORPHINE; MU OPIATE RECEPTOR; MUTANT PROTEIN; NALOXONE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELL STRAIN COS1; CHO CELL; HUMAN; HUMAN CELL; HYDROGEN BOND; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR AFFINITY; RECEPTOR BINDING; SITE DIRECTED MUTAGENESIS;

AMINO ACID SUBSTITUTION; ANIMALS; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; CRICETULUS; CYSTEINE; CYSTINE; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; HUMANS; LIGANDS; MORPHINE; MUTAGENESIS, SITE-DIRECTED; NALOXONE; NARCOTIC ANTAGONISTS; NERVE TISSUE PROTEINS; PEPTIDES; POINT MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 0032847878     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(99)00241-7     Document Type: Article

References (31)

1. 3H ]β-funaltrexamine covalent binding in the cloned rat μ opioid receptor J. Biol. Chem. 271:1996;21422-21429.
2. Cook J.V.F., McGregor A., Lee T.-W., Milligan G., Eidne K.A. A disulfide bonding interaction role for cysteines in the extracellular domain of the thyrotropin-releasing hormone receptor. Endocrinology. 137:1996;2851-2858.
3. 3 receptor with selectivity for opiate alkaloids but without affinity for opioid peptides. Brain Res. 667:1994;229-237.
4. Curtis C.A., Wheatley M., Bansal S., Birdsall N.J., Eveleigh P., Pedder E.K., Poyner D., Hulme E.C. Propylbenzilylcholine mustard labels an acidic residue in transmembrane helix 3 of the muscarinic receptor. J. Biol. Chem. 264:1989;489-495.
5. Cvejic C., Devi L.A. Dimerization of the delta opioid receptor: implication for a role in receptor internalization. J. Biol. Chem. 272:1997;26959-26964.
6. D'Angelo D.D., Eubank J.J., Davis M.G., Dorn II G.W. Mutagenic analysis of platelet thromboxane receptor cysteines. J. Biol. Chem. 271:1996;6233-6240.
7. Ehrlich G.K., Andria M.L., Zheng Z., Kieffer B., Gioannini T.L., Hiller J.M., Rosenkranz J.E., Veksler B.M., Zukin R.S., Simon E.J. Functional significance of cysteine residues in the δ opioid receptor studied by site-directed mutagenesis. Can. J. Physiol. Pharmacol. 76:1998;269-277.
8. Fukuda K., Terasako K., Kato S., Mori K. Identification of the amino acid residues involved in selective agonist binding in the first extracellular loop of the δ- and μ-opioid receptors. FEBS Lett. 373:1995;177-181.
9. Gaibelet G., Capeyrou R., Dietrich G., Emorine L.J. Identification in the μ opioid receptor of cysteine residues responsible for inactivation of ligand binding by thiol alkylating and reducing agents. FEBS Lett. 408:1997;135-140.
10. Gioannini T.L., Liu Y.F., Park Y.-H., Miller J.M., Simon E.J. Evidence for the presence of disulfide bridges in opioid receptors essential for ligand binding. Possible role in receptor activation. J. Mol. Recognit. 2:1989;44-48.
11. Kamikubo K., Murase H., Murayama M., Matsuda M., Miura K. Evidence for disulfide bonds in membrane-bound and solubilized opioid receptors. J. Neurochem. 50:1988;503-509.
12. Karnik S.S., Khorana H.G. Assembly of functional rhodopsin requires a disulfide bond between cysteine residues 110 and 187. J. Biol. Chem. 265:1990;17520-17524.
13. Karnik S.S., Sakmar T.P., Chen H.-B., Khorana H.G. Cysteine residues 110 and 187 are essential for the formation of correct structure in bovine rhodopsin. Proc. Natl. Acad. Sci. USA. 85:1988;8459-8463.
14. Kunkel T.A., Roberts J.D., Zakour R.A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 154:1987;367-382.
15. Lu R., Hubbard J.R., Martin B.R., Kalimi M.Y. Roles of sulfhydryl and disulfide groups in the binding of CP-55,940 to rat brain cannabinoid receptor. Mol. Cell. Biochem. 121:1993;119-126.
16. Meng F., Hoversten M.T., Thompson R.C., Taylor L., Watson S.J., Akil H. A chimeric study of the molecular basis of affinity and selectivity of the κ and the δ opioid receptors. J. Biol. Chem. 270:1995;12730-12736.
17. Metzger T.G., Ferguson D.M. On the role of extracellular loops of opioid receptors in conferring ligand selectivity. FEBS Lett. 375:1995;1-4.
18. Minami M., Onogi T., Nakagawa T., Katao Y., Aoki Y., Katsumata S., Satoh M. DAMGO, a μ-opioid receptor selective ligand, distinguishes between μ- and κ-opioid receptors at a different region from that for the distinction between μ- and δ-opioid receptors. FEBS Lett. 364:1995;23-27.
19. 2-adrenergic receptor requires unique interaction between conserved and nonconserved extracellular loop cysteines. J. Biol. Chem. 269:1994;6743-6752.
20. Onogi T., Minami M., Katao Y., Nakagawa T., Aoki Y., Toya T., Katsumata S., Satoh M. DAMGO, a μ-opioid receptor selective agonist, distinguishes between μ- and δ-opioid receptors around their first extracellular loops. FEBS Lett. 357:1995;93-97.
21. Perlman J.H., Wang W., Nussenzveig D.R., Gershengorn M.C. A disulfide bond between conserved extracellular cysteines in the thyrotropin-releasing hormone receptor is critical for binding. J. Biol. Chem. 270:1995;24682-24685.
22. 2-adrenoceptor binding in cerebral cortex: role of disulfide and sulfhydryl groups. Neurochem. Res. 11:1986;9-27.
23. Savarese T.M., Wang C.D., Fraser C.M. Site-directed mutagenesis of the rat m1 muscarinic acetylcholine receptor: role of conserved cysteines in receptor function. J. Biol. Chem. 267:1992;11439-11448.
24. Shahrestanifar M.S., Howells R.D. Sensitivity of opioid receptor binding to N-substituted maleimides and methanthiosulfonate derivatives. Neurochem. Res. 21:1996;1295-1299.
25. Shahrestanifar M.S., Wang W.W., Howells R.D. Studies on inhibition of μ and δ opioid receptors by dithiothreitol and N-ethylmaleimide. J. Biol. Chem. 271:1996;5505-5512.
26. Sharma P.M., Musacchio J.M. N-ethylmaleimide blocks the modulatory effects of divalent cations and guanine nucleotides on the brain substance P receptor. Eur. J. Pharmacol. 138:1987;9-19.
27. Sidhu A., Kassis S., Kebabian J., Fishman P.H. Sulfhydryl group(s) in the ligand binding site of the D1 dopamine receptor: specific protection by agonist and antagonist. Biochemistry. 25:1986;6695-6701.
28. Simon E.J., Groth J. Kinetics of opiate receptor inactivation by sulfhydryl reagents: evidence for conformational change in the presence of sodium ions. Proc. Natl. Acad. Sci. USA. 72:1975;2404-2407.
29. Surratt C.K., Johnson P.S., Moriwaki A., Seidleck B.K., Blaschak C.J., Wang J.B., Uhl G.R. μ opiate receptor: charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J. Biol. Chem. 269:1994;20548-20553.
30. Wang W.W., Shahrestanifar M., Jin J., Howells R.D. Studies on μ and δ opioid receptor selectivity utilizing chimeric and site-mutagenized receptors. Proc. Natl. Acad. Sci. USA. 92:1995;12436-12440.
31. Wilson H.A., Pasternak G.W., Snyder S.H. Differentiation of opiate agonist and antagonist receptor binding by protein modifying reagents. Nature. 253:1975;448-450.